INTRODUCTION {#S1}
============

Cognitive deficits of schizophrenia are a core feature of schizophrenia and several other neuropsychiatric disorders. Cognitive deficits of schizophrenia are among the first detectable symptoms and are consistent from the first episode throughout middle age ([@R27]). Evidence suggests that cognitive deficits have strong adverse effects on the functional status of schizophrenia patients ([@R24]; [@R22]). The Measure and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) committee identified seven distinct and replicable domains of cognitive deficits of schizophrenia: verbal memory, recognition memory, attention, executive function, social cognition, reasoning, and problem solving ([@R23]).

Current antipsychotic drugs have, at best, modest effects on cognitive deficits of schizophrenia in the vast majority of schizophrenia subjects ([@R20]; [@R27]). There is strong evidence that atypical antipsychotics generally produce an incomplete amelioration of cognitive deficits of schizophrenia, whereas there is controversy regarding whether typical antipsychotics produce an improvement in cognitive deficits of schizophrenia that is comparable to atypical antipsychotics or inferior to them ([@R25]; [@R28]; [@R30]; [@R35]; [@R39]; [@R40]; [@R34]; [@R43]; [@R33]).

Increasing efforts are focused on developing drugs with robust benefits for cognitive deficits of schizophrenia. However, several limitations hamper this effort, including a relative dearth of well-established and validated animal models for these deficits. No single preclinical test is likely to model all domains of cognitive deficits of schizophrenia. Since the pathophysiology of cognitive deficits of schizophrenia, like non-cognitive deficits of schizophrenia features of schizophrenia, is not well understood, developing animal models of cognitive deficits of schizophrenia with etiological validity is challenging. Establishing predictive validity for cognitive deficits of schizophrenia presents another vexing problem since there are no established treatments with complete efficacy.

Pragmatic issues represent still another limitation to the development of new treatments for cognitive deficits of schizophrenia. Most preclinical cognitive tests are labor intensive, requiring training animals on a task for several consecutive days and thus hampering the ability to conduct high-throughput drug screening.

Paradigms examining novelty recognition in animals have been proposed as a valuable preclinical model of cognitive deficits that are seen in schizophrenia ([@R27]). Social recognition and social discrimination are two related examples of preclinical paradigms that assess socially based novelty discrimination and do not require pre-test training of animals ([@R12]).

Investigators have previously focused on pharmacological approaches to induce, in animals, cognitive deficits seen in schizophrenia. For example, Terranova *et al* demonstrated that acute administration of the psychotomimetics PCP and D-amphetamine disrupted social discrimination in Wistar rats ([@R44]). In addition, they found that subchronic administration of PCP during the neonatal period produced spontaneous deficits in social discrimination in adult rats. These deficits were reversed by the atypical antipsychotics clozapine and amisulpride, the putative atypical antipsychotic SSR181507 ([@R44]). These findings suggest that drug-induced disruption of social discrimination may be a useful animal model of cognitive deficits of schizophrenia with predictive utility for potential pro-cognitive drugs. However, in regards to developing animal models with optimal utility for drug discovery, pharmacologically-induced social discrimination deficits have the potential to introduce added experimental complexity, data variability, as well as potentially limiting drug discovery to agents, which specifically block the effects of the deficit-inducing drug ([@R18]). An animal model based on innate social discrimination deficits could therefore provide a complementary alternative approach to those that required experimental manipulation.

Brattleboro (BRAT) rats are Long Evans (LE)-derived rats with a single-gene mutation that disrupts vasopressin secretion ([@R8]). BRAT rats homozygous for the mutation display a number of behaviors that are characteristic of those seen in schizophrenia patients, including abnormalities in memory ([@R32]), stress reactivity ([@R49]), social recognition ([@R11]), and motivation ([@R48]) and attention ([@R48]) (but see, [@R29]). We have shown that BRAT rats exhibit natural schizophrenia-like deficits in prepulse inhibition of startle (PPI), a measure of sensorimotor gating processes. Furthermore, these PPI deficits are reversed by antipsychotics but not non-antipsychotic psychotropics. These findings suggest that the BRAT rat may be a good genetic animal model with predictive validity for antipsychotic drug efficacy. BRAT rats have been shown to exhibit social recognition deficits ([@R11]). Preliminary exploratory studies from our laboratory revealed that BRAT rats also appeared to exhibit deficits compared to LE rats in social discrimination.

The current study had several goals. First, we sought to confirm that BRAT rats exhibit natural social discrimination deficits. We also sought to begin to investigate the response of social discrimination deficits in BRAT to antipsychotics and putative antipsychotics that have been associated with pro-cognitive effects. In that regard, we tested the effects of the atypical antipsychotic clozapine on social discrimination in BRAT and LE rats, since clozapine has been shown to improve learning and delayed recall in schizophrenia patients ([@R51]), two cognitive features required for social discrimination. Furthermore, clozapine reverses the PPI deficits in BRAT rats ([@R15]; [@R13]) and scopolamine-induced social discrimination deficits in rats ([@R44]). We also tested PD149163, which is a brain-penetrating agonist of the neurotensin-1 receptor. PD149163 is a putative antipsychotic drug, reversing PPI deficits in BRAT rats ([@R15]; [@R13]) and demonstrating pro-cognitive effects in novel object recognition, a preclinical test similar to social discrimination ([@R3]).

METHODS {#S2}
=======

Animals {#S3}
-------

Experimental procedures were conducted in accordance with the University of California, San Diego guidelines for animal care and experimentation. All animals were purchased from Harlan Laboratories, San Diego, CA. Ninety-eight adult male BRAT rats and sixty-eight adult male LE rats (170--350 gms at testing) were housed in groups of two or three in clear plastic chambers in a climate controlled room under a 12/12 h light/dark schedule (lights on/off -- 0700/1900). Male Sprague Dawley juvenile rats (25 -- 30 days old) were used as social stimuli. All rats were allowed free access to food and water for the extent of the study. Behavioral testing was performed no earlier than 7 days after animals\' arrival from the breeder. Each adult and each juvenile rat was used only one time.

Behavioral Procedure {#S4}
--------------------

The social discrimination procedure was modified from the social recognition test described by [@R12]. The social discrimination apparatus is made of a large plastic tub (30″ × 17″ × 12″) consisting of two small wire cages (6.5″ × 5″ × 4″) on either ends of the large tub in which the juvenile rats were placed. The purpose of the small wire cages was to restrict mobility of juvenile rats while allowing the adult rat visual, olfactory, and tactile access to the juveniles. This eliminated social contact that was initiated by the juveniles toward the adult. It also prevented simultaneous contact of the adult rat with both juveniles as well as juvenile-juvenile interaction, simplifying social interaction scoring. Each test trial included one adult rat, one familiar, previously exposed juvenile (familiar juvenile), and one novel juvenile. The social discrimination paradigm is illustrated in [Figure 1](#F1){ref-type="fig"}. Briefly, adult rats acclimate in the social discrimination box for 20 minutes. Following this acclimation period, the learning trial begins with the adult rat exposed to a juvenile rat in one of the two small wire cages, randomly selected, for 4 minutes. The adult rat is then returned to its home cage for 30 minutes. During the test trial the adult animal is returned to the social discrimination box. Then the familiar juvenile, along with a novel juvenile, are placed in the two wire cages. In half the trials, the familiar juvenile returns to the same wire cage that the animal was initially placed in during the learning trial. In the other half of the trials, the rat is placed in the alternate wire cage. The adult rat is allotted four minutes to explore the juveniles. All sessions in the social discrimination box are videotaped and the tapes are scored by two raters blinded to the drug treatment and the strain of the rats. Each rater recorded the time each adult rat spent exploring the juvenile during learning trial, and the time the animal spent with the familiar and unfamiliar juvenile during the subsequent test trial.

Drug Treatment {#S5}
--------------

Ten minutes prior to the acclimation period, animals were injected subcutaneously with either saline, clozapine (0.1 mg/kg, 1 mg/kg, 10 mg/kg) or PD149163 (0.1 mg/kg, 0.3 mg/kg or1.0 mg/kg). Social discrimination was then evaluated as described above. These doses selected for clozapine and PD149163 were based on the dose range found to be effective in reversing PPI deficits occurring naturally in BRAT rats and induced by psychotomimetics ([@R15]; [@R13]; [@R17]; [@R14]). Clozapine was obtained from Sigma Chemicals, St. Louis, MO and PD149163 was provided courtesy of NIMH Chemical Synthesis and Drug Supply program, and SRI International, Menlo Park, CA. Clozapine was dissolved in half volume HCl and half volume 0.9% saline then titrated with NaOH to PH 7.0 . PD149163 was dissolved in 0.9% saline. Drugs were administered subcutaneously at a concentration of 1 ml/kg.

Statistical Analysis {#S6}
--------------------

Prior to analysis, data from animals that did not display any interaction (zero seconds) with a juvenile in either the learning or test periods were not included in the analysis, since animals that did not investigate the juvenile during the learning phase (zero seconds) could not be used to generate data on the test trial that could legitimately be considered a reflection of their retention of previous exposure to the juvenile. Similarly, any rat that displayed zero investigation of both novel and familiar juveniles during testing displayed non-investigatory behavior that cannot be considered a valid test of social memory. Ten LE and nineteen BRAT rats given PD149163 and two LE and ten BRAT rats given clozapine were, therefore, eliminated as was one BRAT rat given saline.

A Discrimination Index was calculated to determine preference of adult rats for exploration of the novel juvenile relative to the familiar juvenile in the test session. This index was calculated for each adult rat as percentage increase above the time each it spent exploring the familiar juvenile using the following formula: \[(time exploring novel juvenile - time exploring familiar juvenile) / (time spend exploring familiar juvenile + time spent exploring novel juvenile)\] ([@R21]; [@R42]). Data were analyzed using the SPSS Explore function and extreme outliers (\> 3 standard deviations from the mean excluded from the analysis). One LE rat in the high dose clozapine group and one LE rat in high dose PD149163 group were considered outliers using this analysis.

To determine whether each strain exhibited social discrimination under baseline (saline) conditions, absolute time spent with familiar juvenile and novel juvenile were compared using separate paired samples t-test for saline-treated LE and BRAT rats.

For LE rats, Discrimination Index, time exploring juvenile in the learning phase, time spent exploring familiar juvenile during test phase, and time spent exploring the novel juvenile during the test phase were each subjected to separate one-way ANOVAs with Drug Treatment as a between subject factor having seven elements (saline, clozapine × 3 doses, PD149163 × 3 doses). Drug effects for BRAT rats were assessed separately using an identical approach. Significant effects were followed up with pair-wise post-hoc comparisons using Fishers LSD. Alpha was set at 0.05.

RESULTS {#S7}
=======

Baseline Social Discrimination {#S8}
------------------------------

As shown in [Table 1](#T1){ref-type="table"}, saline-treated LE rats spent significantly more time with the novel juvenile compared to familiar juvenile (t(23)=−2.80, P=0.01), whereas there was no significant difference between the time spent with novel and familiar juveniles among saline-treated BRAT rats ([Table 2](#T2){ref-type="table"}). There was no significant difference between LE and BRAT rats in the average time each strain spent exploring the juvenile rats during the learning period.

Effect of Clozapine and PD149163 on Social Discrimination {#S9}
---------------------------------------------------------

As shown in [Table 1](#T1){ref-type="table"}, analysis of the LE data from the learning exposure period revealed that there was a general tendency for clozapine and PD149163 to reduce the time spent interacting with the juvenile during the learning exposure period although the main effect of drug treatment was not significant. Post hoc pair-wise comparison indicated that the interaction time exhibited by saline-treated LE rats during the learning period was significantly higher than the interaction time exhibited by LE rats treated with the highest dose of clozapine (P\<0.05) and PD149163 (P\<0.05). Analysis of Discrimination Index data revealed no significant main effect of Drug Treatment in the LE rats ([Figure 2](#F2){ref-type="fig"}). Planned post-hoc comparisons revealed that the 0.3 mg/kg dose of PD149163 significantly increased the Discrimination Index relative to saline in LE rats (P\<0.05). There was no significant effect of either drug on the time LE rats spent interacting with the novel juvenile compared to saline. Similarly, there was no significant effect of either drug on the time LE rats spent interacting with the familiar juvenile compared to saline.

In BRAT rats, clozapine and PD149163 produced a more pronounced reduction in exploration of the juvenile during the learning period ([Table 2](#T2){ref-type="table"}) and this was revealed as a significant main effect of Drug Treatment (F~6,97~=5.48, P\<0.001) in this strain. Post-hoc pair-wise comparisons revealed that BRAT rats treated with saline have significantly higher interaction times with the juvenile during the learning period compared with BRAT rats treated with all three doses of clozapine (P=0.047, P=0.023, P=0.013, respectively) and all three doses of PD149163 tested (P=0.002, P\<0.001, and P\<0.001, respectively).

[Figure 3](#F3){ref-type="fig"} illustrates the effects of clozapine and PD149163 on social discrimination in BRAT rats. Analysis of Discrimination Index data revealed there was a significant main effect of drug treatment (F~6,97~=5.79, P\<0.001). Post hoc comparison revealed that the highest dose of clozapine, 10 mg/kg (P\<0.001) and the two highest doses of PD149163, 0.3 mg/kg (P\<0.001) and 1.0 mg/kg (P=0.02) significantly increased the Discrimination Index compared to saline in BRAT rats.

Both clozapine and PD149163 decreased the time BRAT rats spent interacting with the familiar juvenile during the test period ([Table 2](#T2){ref-type="table"}), revealed as a main effect of drug treatment (F~6,104~=4.68, P \< 0.001). Post-hoc comparisons showed that the middle and high doses of clozapine (1.0 mg/kg: P\<0.001, 10.0 mg/kg: P\<0.001) and PD149163 (0.3 mg/kg: P\<0.001, 1.0mg/kg: P=0.006) produced a significant reduction in interaction with the familiar juvenile. There was no significant effect of either drug on the time BRAT rats spend interacting with the novel juvenile compared to saline.

As seen in [Table 1](#T1){ref-type="table"}, neither clozapine nor PD149163 had a significant effect on the time LE rats spent with the novel juvenile during the test period. However in BRAT rats, clozapine and PD149163 tended to produce different effects, neither of which achieved significance. Clozapine tended to decrease, whereas PD149163 tended to increase time spent interacting with the novel juvenile.

DISCUSSION {#S10}
==========

The findings in this report confirm that BRAT rats exhibit natural social discrimination impairment since saline-treated BRAT rats spent comparable amount of time interacting with the novel and familiar juvenile rats. In contrast, saline-treated LE had intact social discrimination as they spent significantly greater time interacting with the novel juvenile. The social discrimination deficits observed in BRAT rats are consistent with previous studies showing that this strain does not exhibit intact social memory in a social recognition paradigm ([@R11]). Moreover, the social discrimination deficit exhibited by BRAT rats seemed to be a true deficit in social memory rather than a non-specific reduction in social motivation or general activity, since saline-treated BRAT and LE rats displayed comparable time exploring the juvenile rat during the learning period.

The BRAT rat, to the best of our knowledge, is the only rat strain to display natural social discrimination deficits. Vasopressin receptor and oxytocin receptor null mice have also been shown to exhibit natural deficits in social memory ([@R7];[@R46]; [@R50]). Oxytocin and vasopressin are chemically and functionally related neurohormones that have both been implicated in the regulation of social behavior.

Prior to this study, BRAT rats were already known to display several features analogous to schizophrenia, including deficits in memory ([@R32]), response to stress ([@R49]), motivation and attention ([@R48]), startle habituation and prepulse inhibition ([@R16]), as well as elevated levels of striatal D2 binding ([@R41]). The current demonstration of natural social discrimination deficits in BRAT rats adds to the schizophrenia-relevant phenotypic profile these animals display.

In this study, the atypical antipsychotic clozapine produced a dose-dependent enhancement of social discrimination in the BRAT rats. Clozapine has been shown to reverse PCP-induced, novel object recognition deficits, an animal test that is very similar to social discrimination ([@R21]) and the current results are consistent with results such as this from related preclinical tests. In regards to clozapine\'s effects on cognitive deficits in humans, a meta-analysis of treatment studies of schizophrenia patients revealed that, overall, clozapine enhances cognitive performance in schizophrenia patients and specifically two cognitive domains relevant to social discrimination: learning and delayed recall ([@R51]). Therefore, it is reasonable to interpret the improvement in BRAT rat social discrimination seen with clozapine as consistent with the clinical experience with clozapine, and thus providing preliminary predictive validity for the BRAT rat model of cognitive deficits. Tests of other antipsychotics will be needed in order to more conclusively establish this contention. However, establishing predictive validity for cognitive deficits of schizophrenia is not a straightforward matter since the benefits of antipsychotics are modest and somewhat controversial. For example, while it is generally accepted that atypical antipsychotics such as clozapine improve cognitive deficits of schizophrenia, there is conflicting evidence regarding whether typical antipsychotics such as haloperidol produce improvements in cognitive deficits of schizophrenia ([@R25]; [@R28]; [@R30]; [@R35]; [@R39]; [@R40]; [@R34]; [@R43]; [@R33]). Haloperidol is not effective in some animal models of cognitive deficits of schizophrenia, namely those based on PCP-induced deficits, whereas it does ameliorate the deficits in other preclinical cognitive deficits of schizophrenia models (e.g. [@R5]; [@R10]; Besbalov *et al*, 2007). Thus, it would be harder to interpret the haloperidol findings in regards to their implications for predictive validity and for that reason we chose to test clozapine in this initial study of cognitive deficits in BRAT rats.

In contrast to its effects in BRAT rats, clozapine did not improve social discrimination in LE rats. In fact, it had the opposite effect, negating the natural social discrimination seen in saline-treated LE rats ([Table 1](#T1){ref-type="table"}). Therefore, the results suggest that the beneficial effects of clozapine on social discrimination were specific to the BRAT rats. This specificity is another aspect that supports validity for cognitive deficits of schizophrenia, since antipsychotics such as clozapine are not considered to be general cognitive enhancers in normal humans or patients that do not have psychotic disorders, and is considered a cognitive impairing drug in humans that do not suffer from schizophrenia or other related psychotic disorders due to its propensity to produce anticholinergic and sedating effects.

PD149163 is an analog of neurotensin, a thirteen amino acid gut-brain peptide. Neurotensin has been proposed to be an endogenous antipsychotic due to, among other things, its ability to inhibit mesolimbic dopamine function ([@R31]). While neurotensin does not enter the brain after systemic administration, PD149163 was designed to do so. This compound was developed by chemically modifying the c-terminal hexapeptide fragment, neurotensin(8-13), the smallest fragment that retains the full bioactivity of neurotensin, to make it more resistant to enzymatic degradation ([@R4]). In previous preclinical studies with PD149163 we found that it produced robust antipsychotic-like effects more similar to atypical than typical antipsychotics. In BRAT rats, a single administration of PD149163 was able to reverse their PPI deficits, as did clozapine but not haloperidol ([@R15]). This effect persisted in BRAT rats after chronic administration of PD149163 ([@R13]). Recently, [@R3] found that PD149163 administered to rats restored novel object recognition impaired by the anticholingergic scopolamine ([@R3]) and that same group also reported that PD149163 increased associative learning in a trace conditioning paradigm ([@R26]). Consistent with those findings and with clozapine effects in this study, acute administration of PD149163 improved social discrimination in this study in BRAT rats, but unlike clozapine the most effective dose of PD149163 in BRAT rats (0.3 mg/kg) also improved social discrimination in LE rats.

The social discrimination test is based upon the social recognition test in which only the familiar juvenile is re-introduced during the testing session and reduction in time spent investigating that juvenile is evidence of intact social memory ([@R11]). The introduction of a second, novel juvenile in the discrimination test was used primarily to control for non-specific reductions in investigation, e.g. sedation, that might affect the second exposure. The improvement in Discrimination Index scores by clozapine and PD149163 in this study was due specifically to decrease in the time investigating the familiar juveniles, whereas investigation time of the new juveniles was not altered. Thus, the effect produced by clozapine and PD149163 of reduced exploration of the familiar juvenile is the classical operational measure of social memory ([@R11]).

The exact mechanisms underlying PD149163\'s pro-cognitive effects in this and previous studies are not known. PD149163 is selective for the NT1 receptor ([@R38]), the neurotensin receptor subtype most implicated in neurotensin\'s antipsychotic-like effect. Azmi *et al* speculate the NT1-mediated enhancement of muscarinic transmission may be involved. PD149163 has also been shown to increase neuronal activation in the prefrontal cortex ([@R3]) and this activation may contribute to its cognitive effects ([@R38]). In any case, these results enhance the candidacy of NT1 agonists as potentially novel antipsychotics that may have benefit for cognitive deficits of schizophrenia. It is interesting that the dose of PD149163 that was most effective in increasing social discrimination in BRAT rats (0.3 mg/kg) also improved social discrimination LE rats. This suggests that PD149163 may facilitate non-impaired memory.

It is noteworthy that both clozapine and PD149163 enhanced social discrimination in test trials despite that both drugs reduced exploration time of LE and BRAT rats during the learning period. This reduction in exploration during the learning period is likely due to a non-specific inhibitory effect on activity since both drugs are known to decrease spontaneous locomotor activity ([@R47]; [@R37]). Thus, it appears that the reduction in exploratory contact during the learning period produced by clozapine and PD149163 was more than compensated for by enhanced information acquisition during this period in BRAT rats but not LE rats; in essence, clozapine produced more efficient learning in BRAT rats (more retention despite less opportunity to learn). This seemingly paradoxical effect has been reported with PD149163 and atypical antipsychotics in the novel object recognition test which is similar to social discrimination ([@R3]; [@R36]). Indeed, among rats treated with clozapine and PD149163, there was a inverse relationship between time spent interacting with the juvenile during the learning phase and their subsequent social discrimination performance (Pearson r = −0.182, p=0.06); the more a rat\'s learning period interaction was suppressed, the better they performed subsequently on social discrimination. Therefore, the mechanism underlying the reduction of spontaneous locomotion produced by these drugs may also be involved in the enhanced cognitive performance. Some rats treated with higher doses of clozapine and PD149163 had to be eliminated from the data analysis altogether, since they displayed a profound reduction in spontaneous locomotion and no interaction at all (zero seconds) with the juvenile during the learning period. It is unlikely that this selective elimination of rats contributed to the positive finding on the social discrimation performance that we observed due to the inverse relationship noted above between interaction suppression and enhancement of social discrimination.

In this study clozapine and PD149163 improved social discrimination after a single administration. This is consistent with most other preclinical tests of antipsychotics and other cognitive enhancing treatments where significant effects are seen following a single dose. It is commonly believed that improvement of cognitive deficits of schizophrenia occurs only with chronic use of antipsychotics and not after a single dose. However, a similar common assumption about the time course of antipsychotic drug benefits on the core symptoms of schizophrenia has recently been proven inaccurate by recent meta-analyses of clinical data that reveal significant benefits begin after a single dose of antipsychotics but require chronic use to achieve optimal effects ([@R2]; [@R1]). It is possible therefore that the same holds true for improvement in cognitive deficits of schizophrenia by antipsychotics, but the time course of antipsychotic-induced cognitive deficits of schizophrenia improvements has not been studied. In this regard, we have shown that the natural PPI deficits in BRAT rats are enhanced by a single administration of atypical antipsychotics and this effect increases with chronic administration ([@R13]). Future studies should investigate the relative effects of acute and chronic clozapine, PD149163 and other antipsychotics on social discrimination deficits in BRAT rats.

Social discrimination abnormalities in BRAT rats, like the PPI deficits exhibited by this rat strain, may serve as a genetic animal model of schizophrenia cognitive deficits. Further study of this model may aid in elucidating novel genes or pathways implicated in the neuropathology of the disorder. In addition, the results of this study serve as preliminary evidence that the social discrimination deficits in BRAT rats may serve as a predictive model of novel antipsychotic efficacy in cognitive domains.
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![Illustration of the Social Discrimination Paradigm. Adult rats acclimate in the social discrimination box for 20 minutes. Following this acclimation period, the learning trial begins with the adult rat exposed to a juvenile rat for 4 minutes. The adult rat is then returned to its home cage for 30 minutes. During the retrieval trial the adult animal returns to the chamber with the introduction of a new juvenile along with the same juvenile from the learning trial for 4 minutes. The positions of the juveniles are randomly alternated](nihms-86159-f0001){#F1}

![The effects of saline (n=20), PD149163 and clozapine (n = 7-8 per dose) on the Discrimination Index in LE rats. Discrimination Index equals (time spent investigating new juvenile - time spent investigating familiar juvenile) / (time spent investigating new juvenile + time spent investigating familiar juvenile). Significantly higher than saline is represented by \* (P\< 0.05).](nihms-86159-f0002){#F2}

![The effects of saline (n = 36), PD149163 and clozapine (n = 11-15 per dose) on the Discrimination Index in BRAT rats. Discrimination Index equals (time spent investigating new juvenile - time spent investigating familiar juvenile) / (time spent investigating new juvenile + time spent investigating familiar juvenile). Significantly higher than saline is represented by \* (P\< 0.05) and \*\* (P\< 0.01).](nihms-86159-f0003){#F3}

###### 

Social Interaction Time (seconds) Exhibited by Long Evans Rats

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TRIAL               SALINE          CLOZAPINE (mg/kg)   PD149163 (mg/kg)                                                                                      
  ------------------- --------------- ------------------- ------------------ ------------------------------------------------ ---------------- ---------------- -----------------------------------------------
  Learning Exposure   142.13 ± 8.10   113.00 ± 13.85      114.50 ± 9.88      102.71 ± 12.84[\*](#TFN1){ref-type="table-fn"}   107.00 ± 20.65   104.38 ± 28.21   100.14 ±12.26[\*](#TFN1){ref-type="table-fn"}

                                                                                                                                                                

  Test Period-\       49.29 ± 5.11    52.13 ± 8.60        67.71 ± 16.85      60.37 ± 16.31                                    62.88 ± 12.01    61.13 ± 17.46    52.58 ± 11.76
  Familiar Juvenile                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mean ± Std.

Error Mean P\< 0.05, significantly less time spent investigating versus the saline-treated rats

P\<0.05, significantly greater compared to familiar juvenile.

###### 

Social Interaction Time (seconds) Exhibited by Brattleboro Rats

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TRIAL               SALINE          CLOZAPINE (mg/kg)   PD149163 (mg/kg)                                                                                                                                                                                      
  ------------------- --------------- ------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  Learning Exposure   125.71 ± 6.71   91.13 ± 18.09       88.33 ± 14.10                                    85.50 ± 15.97[\*](#TFN3){ref-type="table-fn"}    72.36 ± 22.26[\*\*](#TFN4){ref-type="table-fn"}   53.27 ± 12.42[\*\*](#TFN4){ref-type="table-fn"}   69.60 ± 14.96[\*\*](#TFN4){ref-type="table-fn"}

  Test Period-\       55.10 ± 3.90    43.50 ± 10.91       41.67 ± 8.48                                     50.63 ± 14.32                                    62.64 ± 10.57                                     55.27 ± 13.89                                     66.87 ± 14.85
  Novel Juvenile                                                                                                                                                                                                                                                

  Test Period-\       47.38 ± 3.46    44.88 ± 8.87        20.67 ± 4.41[\*\*](#TFN4){ref-type="table-fn"}   21.13 ± 5.34[\*\*](#TFN4){ref-type="table-fn"}   47.09 ± 7.35                                      24.09 ± 7.94[\*\*](#TFN4){ref-type="table-fn"}    31.13 ± 8.11[\*](#TFN3){ref-type="table-fn"}
  Familiar Juvenile                                                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mean ± Std.

Error Mean P\< 0.05 significantly less time spent investigating versus the saline-treated rats.

Error Mean P\<0.01 significantly less time spent investigating versus the saline-treated rats.
